SCHEMBL4773489

SCHEMBL4773489

CCC(Cc1ccc(C)c(O)c1)Nc1cc(-c2cccnc2)nc(-c2ccccn2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2A6 P11509 1/20 0.39
NPC1 O15118 1/20 0.37
TP53 P04637 1/20 0.37
PKM P14618 1/20 0.37
TSHR P16473 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
DYRK1A Q13627 2/20 0.36
DYRK3 O43781 1/20 0.36
CCNT1 O60563 1/20 0.36
CCNA2 P20248 1/20 0.36
CDK2 P24941 1/20 0.36
CDK9 P50750 1/20 0.36
CDK5 Q00535 1/20 0.36
CDK5R1 Q15078 1/20 0.36
DYRK2 Q92630 1/20 0.36
DYRK1B Q9Y463 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4774839 0.84 DYRK1A (0.51) CYP3A4CYP2C9CYP2A6NPC1TP53
SCHEMBL4773536 0.80 CYP2A6 (0.44) CYP3A4CYP2C9CYP2A6NPC1TP53
SCHEMBL4773513 0.80 CYP2A6 (0.44) CYP3A4CYP2C9CYP2A6NPC1TP53
SCHEMBL4775017 0.80 CYP2A6 (0.44) CYP3A4CYP2C9CYP2A6NPC1TP53
SCHEMBL3962923 0.78 CYP2A6 (0.43) CYP3A4CYP2C9CYP2A6NPC1TP53
SCHEMBL2238401 0.75 CYP2A6 (0.41) CYP3A4CYP2C9CYP2A6NPC1TP53
SCHEMBL4773182 0.74 CYP2A6 (0.39) CYP3A4CYP2C9CYP2A6NPC1TP53
SCHEMBL4773165 0.74 CYP2A6 (0.39) CYP3A4CYP2C9CYP2A6NPC1TP53
SCHEMBL2239081 0.73 CLK4 (0.54) CYP3A4CYP2C9CYP2A6SMN1; SMN2DYRK1A
SCHEMBL3962124 0.72 CYP2A6 (0.46) CYP3A4CYP2C9CYP2A6NPC1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1878733-A1 Pyrimidine derivatives as ALK-5 inhibitors Novartis AG (CH) 2008-01-16 EP disclosed